Therapeutic effects of IL-12 combined with benzoylmesaconine, a non-toxic aconitine-hydrolysate, against herpes simplex virus type 1 infection in mice following thermal injury

Makiko Kobayashi, Hitoshi Takahashi, David Herndon, Richard B. Pollard, Fujio Suzuki

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

IL-12 is an inducer of type 1 T cell responses, which are essential in host defense against herpes simplex virus type 1 (HSV-1) infection. However, type 1 T cell responses are not elicited by IL-12 in thermally injured mice (TI-mice) that routinely have a predominance of burn-associated type 2 T cell responses. In our previous studies, benzoylmesaconine (BEN, an aconitine derivative extracted from heated-Aconiti tuber) induced the generation of CD4+ T cells antagonistic to type 2 T cells (BEN-CD4+ T cells). In the present study, the effects of a combination therapy using IL-12 and BEN to treat severe HSV-1 infection in TI-mice were investigated. When TI-mice were treated with either IL-12 (500U per mouse) or BEN (1μg/kg) alone, they did not resist HSV-1 infection. However, 60-80% of TI-mice exposed to HSV-1 survived after they received IL-12 and BEN or BEN-CD4+ T cells in combination. After stimulation with anti-CD3 mAb in vitro, IFN-γ was not produced in cultures of splenic T cells from TI-mice exposed to HSV-1 and treated with either IL-12, BEN or BEN-CD4+ T cell alone. However, IFN-γ production was induced by the mAb stimulation in the cultures of T cells from infected mice treated with IL-12 and BEN or BEN-CD4+ T cells in combination. These results suggest that the combination therapy of IL-12 (an inducer of type 1 T cell responses) and BEN (an inhibitor of type 2 T cell responses) may protect TI-mice from severe HSV-1 infection.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalBurns
Volume29
Issue number1
DOIs
StatePublished - Feb 2003

Fingerprint

Aconitine
Human Herpesvirus 1
Therapeutic Uses
Virus Diseases
Interleukin-12
Hot Temperature
T-Lymphocytes
Wounds and Injuries
benzoylmesaconine
Burns

Keywords

  • Benzoylmesaconine
  • Burn injury
  • Herpes simplex virus
  • IL-12

ASJC Scopus subject areas

  • Emergency Medicine
  • Surgery

Cite this

Therapeutic effects of IL-12 combined with benzoylmesaconine, a non-toxic aconitine-hydrolysate, against herpes simplex virus type 1 infection in mice following thermal injury. / Kobayashi, Makiko; Takahashi, Hitoshi; Herndon, David; Pollard, Richard B.; Suzuki, Fujio.

In: Burns, Vol. 29, No. 1, 02.2003, p. 37-42.

Research output: Contribution to journalArticle

@article{f840ef7a94a54141831948dff784c1ac,
title = "Therapeutic effects of IL-12 combined with benzoylmesaconine, a non-toxic aconitine-hydrolysate, against herpes simplex virus type 1 infection in mice following thermal injury",
abstract = "IL-12 is an inducer of type 1 T cell responses, which are essential in host defense against herpes simplex virus type 1 (HSV-1) infection. However, type 1 T cell responses are not elicited by IL-12 in thermally injured mice (TI-mice) that routinely have a predominance of burn-associated type 2 T cell responses. In our previous studies, benzoylmesaconine (BEN, an aconitine derivative extracted from heated-Aconiti tuber) induced the generation of CD4+ T cells antagonistic to type 2 T cells (BEN-CD4+ T cells). In the present study, the effects of a combination therapy using IL-12 and BEN to treat severe HSV-1 infection in TI-mice were investigated. When TI-mice were treated with either IL-12 (500U per mouse) or BEN (1μg/kg) alone, they did not resist HSV-1 infection. However, 60-80{\%} of TI-mice exposed to HSV-1 survived after they received IL-12 and BEN or BEN-CD4+ T cells in combination. After stimulation with anti-CD3 mAb in vitro, IFN-γ was not produced in cultures of splenic T cells from TI-mice exposed to HSV-1 and treated with either IL-12, BEN or BEN-CD4+ T cell alone. However, IFN-γ production was induced by the mAb stimulation in the cultures of T cells from infected mice treated with IL-12 and BEN or BEN-CD4+ T cells in combination. These results suggest that the combination therapy of IL-12 (an inducer of type 1 T cell responses) and BEN (an inhibitor of type 2 T cell responses) may protect TI-mice from severe HSV-1 infection.",
keywords = "Benzoylmesaconine, Burn injury, Herpes simplex virus, IL-12",
author = "Makiko Kobayashi and Hitoshi Takahashi and David Herndon and Pollard, {Richard B.} and Fujio Suzuki",
year = "2003",
month = "2",
doi = "10.1016/S0305-4179(02)00248-6",
language = "English (US)",
volume = "29",
pages = "37--42",
journal = "Burns",
issn = "0305-4179",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Therapeutic effects of IL-12 combined with benzoylmesaconine, a non-toxic aconitine-hydrolysate, against herpes simplex virus type 1 infection in mice following thermal injury

AU - Kobayashi, Makiko

AU - Takahashi, Hitoshi

AU - Herndon, David

AU - Pollard, Richard B.

AU - Suzuki, Fujio

PY - 2003/2

Y1 - 2003/2

N2 - IL-12 is an inducer of type 1 T cell responses, which are essential in host defense against herpes simplex virus type 1 (HSV-1) infection. However, type 1 T cell responses are not elicited by IL-12 in thermally injured mice (TI-mice) that routinely have a predominance of burn-associated type 2 T cell responses. In our previous studies, benzoylmesaconine (BEN, an aconitine derivative extracted from heated-Aconiti tuber) induced the generation of CD4+ T cells antagonistic to type 2 T cells (BEN-CD4+ T cells). In the present study, the effects of a combination therapy using IL-12 and BEN to treat severe HSV-1 infection in TI-mice were investigated. When TI-mice were treated with either IL-12 (500U per mouse) or BEN (1μg/kg) alone, they did not resist HSV-1 infection. However, 60-80% of TI-mice exposed to HSV-1 survived after they received IL-12 and BEN or BEN-CD4+ T cells in combination. After stimulation with anti-CD3 mAb in vitro, IFN-γ was not produced in cultures of splenic T cells from TI-mice exposed to HSV-1 and treated with either IL-12, BEN or BEN-CD4+ T cell alone. However, IFN-γ production was induced by the mAb stimulation in the cultures of T cells from infected mice treated with IL-12 and BEN or BEN-CD4+ T cells in combination. These results suggest that the combination therapy of IL-12 (an inducer of type 1 T cell responses) and BEN (an inhibitor of type 2 T cell responses) may protect TI-mice from severe HSV-1 infection.

AB - IL-12 is an inducer of type 1 T cell responses, which are essential in host defense against herpes simplex virus type 1 (HSV-1) infection. However, type 1 T cell responses are not elicited by IL-12 in thermally injured mice (TI-mice) that routinely have a predominance of burn-associated type 2 T cell responses. In our previous studies, benzoylmesaconine (BEN, an aconitine derivative extracted from heated-Aconiti tuber) induced the generation of CD4+ T cells antagonistic to type 2 T cells (BEN-CD4+ T cells). In the present study, the effects of a combination therapy using IL-12 and BEN to treat severe HSV-1 infection in TI-mice were investigated. When TI-mice were treated with either IL-12 (500U per mouse) or BEN (1μg/kg) alone, they did not resist HSV-1 infection. However, 60-80% of TI-mice exposed to HSV-1 survived after they received IL-12 and BEN or BEN-CD4+ T cells in combination. After stimulation with anti-CD3 mAb in vitro, IFN-γ was not produced in cultures of splenic T cells from TI-mice exposed to HSV-1 and treated with either IL-12, BEN or BEN-CD4+ T cell alone. However, IFN-γ production was induced by the mAb stimulation in the cultures of T cells from infected mice treated with IL-12 and BEN or BEN-CD4+ T cells in combination. These results suggest that the combination therapy of IL-12 (an inducer of type 1 T cell responses) and BEN (an inhibitor of type 2 T cell responses) may protect TI-mice from severe HSV-1 infection.

KW - Benzoylmesaconine

KW - Burn injury

KW - Herpes simplex virus

KW - IL-12

UR - http://www.scopus.com/inward/record.url?scp=0037304350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037304350&partnerID=8YFLogxK

U2 - 10.1016/S0305-4179(02)00248-6

DO - 10.1016/S0305-4179(02)00248-6

M3 - Article

VL - 29

SP - 37

EP - 42

JO - Burns

JF - Burns

SN - 0305-4179

IS - 1

ER -